The FDA has approved #semaglutide for treating chronic kidney disease #CKD in adults with type 2 diabetes to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death, based on the results of the FLOW trial which demonstrated a 24% reduction in major kidney disease events compared to placebo
Performed exclusively by GMC Specialist Register plastic surgeons at Centre for Surgery not nurses, dentists, or non-specialist doctors
Dhar S, Vemulapalli V, Patananan AN, Huang GL, Di Lorenzo A, Richard S
Afshar, S., Roderick, P
Panels combining multiple serum markers show improved performance compared to single markers but require further validation
If the solution shows signs of degradation, do not use it